Patents by Inventor Simon McKenzie
Simon McKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11806362Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.Type: GrantFiled: April 25, 2022Date of Patent: November 7, 2023Assignee: Agency for Science, Technology and ResearchInventors: Raymond Alexander Alfred Smith, Simon McKenzie Cool, Victor Nurcombe, Sadasivam Murali
-
Publication number: 20220347205Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.Type: ApplicationFiled: April 25, 2022Publication date: November 3, 2022Inventors: Raymond Alexander Alfred Smith, Simon McKenzie Cool, Victor Nurcombe, Sadasivam Murali
-
Patent number: 11331337Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.Type: GrantFiled: December 11, 2018Date of Patent: May 17, 2022Assignee: Agency for Science, Technology and ResearchInventors: Raymond Alexander Alfred Smith, Simon McKenzie Cool, Victor Nurcombe, Sadasivam Murali
-
Publication number: 20210161945Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.Type: ApplicationFiled: December 11, 2018Publication date: June 3, 2021Inventors: Raymond Alexander Alfred Smith, Simon McKenzie Cool, Victor Nurcombe
-
Patent number: 10245301Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.Type: GrantFiled: September 12, 2016Date of Patent: April 2, 2019Assignee: Agency for Science, Technology and ResearchInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Patent number: 10220054Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.Type: GrantFiled: October 27, 2016Date of Patent: March 5, 2019Assignee: Agency for Science, Technology and ResearchInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Publication number: 20180360916Abstract: The isolation and identification of glycosaminoglycans capable of binding to proteins having a heparin-binding domain is disclosed, as well as the use of the glycosaminoglycans isolated in the growth and/or development of tissue.Type: ApplicationFiled: June 27, 2018Publication date: December 20, 2018Inventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Patent number: 10086044Abstract: The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS).Type: GrantFiled: September 11, 2009Date of Patent: October 2, 2018Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Publication number: 20170106012Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.Type: ApplicationFiled: October 27, 2016Publication date: April 20, 2017Inventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Publication number: 20160375099Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Inventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Patent number: 9498494Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.Type: GrantFiled: September 5, 2012Date of Patent: November 22, 2016Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Patent number: 9205106Abstract: The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia.Type: GrantFiled: September 7, 2009Date of Patent: December 8, 2015Assignee: Agency for Science, Technology and ResearchInventors: Simon McKenzie Cool, Victor Nurcombe
-
Publication number: 20130045249Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.Type: ApplicationFiled: September 5, 2012Publication date: February 21, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Patent number: 8287853Abstract: Stem cells obtained through in vitro culture with heparan sulphate are described.Type: GrantFiled: August 8, 2008Date of Patent: October 16, 2012Assignee: Agency for Science, Technology and ResearchInventors: Simon McKenzie Cool, Victor Nurcombe
-
Publication number: 20110165132Abstract: The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS).Type: ApplicationFiled: September 11, 2009Publication date: July 7, 2011Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Publication number: 20110165218Abstract: The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia.Type: ApplicationFiled: September 7, 2009Publication date: July 7, 2011Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe
-
Publication number: 20110159071Abstract: The isolation and identification of glycosaminoglycans capable of binding to proteins having a heparin-binding domain is disclosed, as well as the use of the glycosaminoglycans isolated in the growth and/or development of tissue.Type: ApplicationFiled: February 19, 2009Publication date: June 30, 2011Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie Cool, Victor Nurcombe, Christian Dombrowski
-
Publication number: 20090148420Abstract: Stem cells obtained through in vitro culture with heparan sulphate are described.Type: ApplicationFiled: August 8, 2008Publication date: June 11, 2009Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon McKenzie COOL, Victor NURCOMBE
-
Publication number: 20070041987Abstract: An isolated fusion protein is provided which is a conjugate of a therapeutic polypeptide and an albumin fragment, such as a fragment including an individual domain or subdomain of albumin, or a polymer of albumin (e.g., dimers, trimers, etc.) and which is used to optimize the half-life of that therapeutic agent in the bloodstream in a tunable fashion based on the molecular weight of the fragment or polymer. Albumin fragments useful in the invention include fragments containing any of the individual domains and subdomains of human serum albumin, as well as fragments including specific combinations of binding regions or subdomains. The present invention thus provides fragments or polymers which will allow for optimizing half-lives of therapeutic polypeptides depending on their molecular weight, and this will optimizes protein and vaccine therapeutics to have desired half lives for their greatest effectiveness.Type: ApplicationFiled: March 19, 2004Publication date: February 22, 2007Inventors: Daniel Carter, Simon McKenzie, Florian Ruker